Synonyms: VVZ-149 | VVZ149
Compound class:
Synthetic organic
Comment: Opiranserin (VVZ-149) is a dual glycine transporter 2 (GlyT2) inhibitor and serotonin 5-HT2A receptor antagonist [1]. It was developed as a novel non-opioid analgesic.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Opiranserin (VVZ-149) has progressed to late stage clinical evaluation as a postoperative pain therapeutic. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03997838 | Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following Abdominoplasty | Phase 3 Interventional | Vivozon, Inc. | ||
NCT04430088 | Phase 3 Efficacy and Safety Study of VVZ-149 Injections for Postoperative Pain Following Bunionectomy | Phase 3 Interventional | Vivozon, Inc. | ||
NCT01905410 | Phase I Study to Investigate Safety, Tolerability, and Pharmacokinetics of VVZ-149 Injection | Phase 1 Interventional | Vivozon, Inc. | VVZ-149 injections were well tolerated in healthy male volunteers. | 1 |